Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 10/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340087 | 0.93 | TDP1 (0.44) | KDM4ESMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL21667598 | 0.91 | LMNA (0.39) | KDM4ESMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL21667422 | 0.87 | TDP1 (0.49) | KDM4ESMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL15041040 | 0.86 | TDP1 (0.42) | KDM4ESMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL22186542 | 0.86 | KMT2A (0.42) | KDM4ESMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL24128475 | 0.85 | PDK2 (0.46) | KDM4ESMN1; SMN2LMNAALDH1A1L3MBTL1 | |
| SCHEMBL13614957 | 0.85 | PDK2 (0.40) | PDK2 | |
| SCHEMBL13614935 | 0.85 | LPL (0.38) | KDM4ESMN1; SMN2LMNAPDK2 | |
| SCHEMBL13614972 | 0.85 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2LMNAALDH1A1HPGD | |
| SCHEMBL30009790 | 0.84 | PDK2 (0.50) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612204-B2 | Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612204-B2 | Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| WO-2008047589-A1 | QUINOXALINE DERIVATIVE, AND LIGHT-EMITTING ELEMENT AND LIGHT-EMITTING DEVICE USING QUINOXALINE DERIVATIVE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-04-24 | — | — | WO | disclosed |
| US-20080091012-A1 | Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080091012-A1 | Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091012-A1 | Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative | NQO1, GLB1, PDXK | KDM4E 2134/4885SMN1; SMN2 3777/4885LMNA 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.